Key terms
About RCM
R1 RCM, Inc. engages in the provision of revenue cycle management to healthcare providers. It offers end-to-end, modular revenue cycle, and physician advisory services. The company was founded by Mary Ann Tolan and J. Michael Cline in July 2003 and is headquartered in Murray, UT.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest RCM news
Apr 18
6:36am ET
R1 RCM (RCM) Gets a Buy from RBC Capital
Apr 05
6:30am ET
R1 RCM price target lowered to $15 from $17 at Guggenheim
Apr 01
7:19am ET
Truist Financial Reaffirms Their Hold Rating on R1 RCM (RCM)
Mar 20
7:17am ET
Truist Financial Sticks to Their Hold Rating for R1 RCM (RCM)
Mar 20
7:03am ET
R1 RCM price target lowered to $16 from $17 at Canaccord
Mar 20
4:45am ET
Buy Rating Affirmed for R1 RCM Amid Strong Fundamentals and Prospective Acquisition
Mar 20
4:40am ET
R1 RCM upgraded to Buy from Neutral at Citi
Mar 19
9:10am ET
LifeStance named Top Pick in Healthcare Technology at Morgan Stanley
Mar 19
8:40am ET
R1 RCM Committee says talks with New Mountain, TCP-ASC must stop for now
Mar 13
2:11am ET
Analysts Are Bullish on Top Healthcare Stocks: Biogen (BIIB), Merck & Company (MRK)
Mar 11
9:50pm ET
Analysts Offer Insights on Healthcare Companies: Maravai Lifesciences Holdings (MRVI) and R1 RCM (RCM)
Mar 11
9:35am ET
Hold Rating on R1 RCM Amid Acquisition Talks and Valuation Considerations
Mar 11
8:22am ET
R1 RCM forms special committee to evaluate strategic alternatives
Mar 11
12:35am ET
R1 RCM Poised for Growth: Outperform Rating and $17 Target Justified by Strong LBO Potential and Historical Multiples
Mar 04
5:35pm ET
Maintaining Hold on R1 RCM Amid Acquisition Proposal and Mixed Financial Outlook
Mar 04
5:29pm ET
R1 RCM downgraded to Hold from Buy at Truist
Mar 01
6:30am ET
R1 RCM downgraded to Neutral from Buy at Citi
Mar 01
1:17am ET
Buy Rating Affirmed on R1 RCM Amid Strong Q4 Performance and Pragmatic FY2024 Outlook
Feb 28
10:20am ET
Analysts Are Bullish on These Healthcare Stocks: Kura Oncology (KURA), uniQure (QURE)
Feb 28
7:47am ET
TD Cowen Keeps Their Buy Rating on R1 RCM (RCM)
Feb 28
4:48am ET
R1 RCM downgraded to Equal Weight from Overweight at Barclays
Feb 27
11:38pm ET
Buy Rating Justified: R1 RCM’s Undervalued Growth Potential and Market Position Strength
Feb 27
4:05pm ET
R1 RCM downgraded to In Line from Outperform at Evercore ISI
Feb 27
4:05pm ET
R1 RCM downgraded to In Line from Outperform at Evercore ISI
Feb 27
7:12am ET
R1 RCM to Discuss Quarterly and Annual Financial Results
Feb 27
7:04am ET
R1 RCM sees FY24 revenue $2.625B-$2.675B, consensus $2.69B
Feb 27
7:03am ET
R1 RCM reports Q4 EPS 0c, consensus 2c
Feb 27
3:30am ET
Analysts Offer Insights on Healthcare Companies: Fate Therapeutics (FATE), Elanco Animal Health (ELAN) and R1 RCM (RCM)
Feb 26
4:15pm ET
R1 RCM Hold Rating Justified Amid Buyout Proposal and Market Dynamics
Feb 26
4:06pm ET
R1 RCM downgraded to Hold from Buy at Deutsche Bank
Feb 26
3:58pm ET
Coliseum Capital says New Mountain bid indication undervalues R1 RCM
No recent press releases are available for RCM
RCM Financials
Key terms
Ad Feedback
RCM Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
RCM Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range